



HAL
open science

Occurrence and removal of emerging pollutants in urban sewage treatment plants using LC-QToF-MS suspect screening and quantification

Laure Wiest, Antoine Gosset, Aurélie Fildier, Christine Libert, Matthieu Hervé, Elisabeth Sibeud, Barbara Giroud, Emmanuelle Vulliet, Thérèse Bastide, Philippe Polomé, et al.

► To cite this version:

Laure Wiest, Antoine Gosset, Aurélie Fildier, Christine Libert, Matthieu Hervé, et al.. Occurrence and removal of emerging pollutants in urban sewage treatment plants using LC-QToF-MS suspect screening and quantification. *Science of the Total Environment*, 2021, 774, pp.145779. 10.1016/j.scitotenv.2021.145779 . hal-03162034

HAL Id: hal-03162034

<https://univ-lyon1.hal.science/hal-03162034>

Submitted on 29 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Occurrence and removal of emerging pollutants in urban sewage treatment plants using LC-**
2 **QToF-MS suspect screening and quantification.**

3 Laure Wiest¹, Antoine Gosset^{2,3,4*}, Aurélie Fildier¹, Christine Libert⁵, Matthieu Hervé⁵, Elisabeth
4 Sibeud⁵, Barbara Giroud¹, Emmanuelle Vulliet¹, Thérèse Bastide¹, Philippe Polomé³, Yves Perrodin²

5 ¹ Univ Lyon, CNRS, Université Claude Bernard Lyon 1, Institut des Sciences Analytiques, UMR
6 5280, 5 Rue de la Doua, F-69100 Villeurbanne, France

7 ² Université de Lyon, Université Claude Bernard Lyon 1, CNRS, ENTPE, UMR5023 LEHNA, F-
8 69518, Vaulx-en-Velin, France

9 ³ Université de Lyon & Université Lyon 2, Lyon, F-69007, France ; CNRS, UMR 5824 GATE Lyon
10 Saint-Etienne, Ecully, F-69130, France

11 ⁴ Ecole Urbaine de Lyon, Institut Convergences, Commissariat général aux investissements d'avenir,
12 Bât. Atrium, 43 Boulevard du 11 Novembre 1918, F-69616 Villeurbanne, France

13 ⁵ Greater Lyon Urban Community, Water and Urban Planning Department, 69003 Lyon, France

14 *Corresponding author: antoinegosset@hotmail.com

15

16 Abstract

17 Urban wastewaters (WW) are a major vector of many emerging pollutants (EPs) to aquatic
18 ecosystems, as urban wastewater treatment plants (WWTPs) are not designed to abate them. New
19 methods are now critically necessary for a more comprehensive analysis of WW samples and for the
20 assessment of the WWTP efficiency in EP removal. To this end, the present study aims to develop a
21 methodology to identify and quantify EPs, especially pharmaceutical residues and pesticides, in the
22 raw and treated wastewater of 10 heterogeneous WWTPs in a highly urbanized territory in France
23 over three sampling campaigns, through the following steps: (1) development and implementation
24 of a suspect screening of EPs in WW samples, based on a solid phase extraction followed by an LC-
25 QToF-MS analysis; (2) confirmation of their identification by reinjection of WW samples spiked
26 with authentic analytical standards; (3) quantification of previously identified compounds by targeted
27 LC-QToF-MS analysis in raw and treated effluents and assessment of their removal efficiency by
28 WWTPs. Forty-one EPs, including 37 pharmaceutical residues (such as anti-depressive, anti-
29 hypertensive, or antipsychotic drugs) and 4 pesticides, were identified by suspect screening. Some
30 of them (e.g. milnacipran) are reported for the first time in urban WWTPs in this study. High
31 variability in detection frequency and concentrations were observed in function of the EP and
32 WWTP. Nevertheless, median removal rates were considered negative or low for more than 50 % of

33 the EPs (respectively 4 and 17), leading to a quantification of significant concentrations in treated
34 WW. Their release into receiving streams may thus lead to ecotoxicological risks that should be
35 evaluated in order to prevent any degradation of the exposed ecosystems.

36 Key-words

37 Emerging pollutants; Wastewater; Chemical analysis; Suspect-screening; Pharmaceuticals;
38 Removal efficiency

39

40 1. Introduction

41 Emerging pollutants (EPs), such as pharmaceutical residues, have now been widely observed in
42 various aquatic compartments (e.g. streams, lakes, groundwaters) (Gavrilescu et al., 2015; López-
43 Pacheco et al., 2019; Pinasseau et al., 2019; Vulliet and Cren-Olivé, 2011). Most of them are a great
44 threat to communities of aquatic organisms, as they can cause significant acute and chronic ecotoxic
45 effects at low concentrations (Orias and Perrodin, 2013; Gosset et al., 2017). Urban wastewaters
46 (WW) are a major vector of many EPs to aquatic ecosystems, as urban wastewater treatment plants
47 (WWTPs) are not designed to abate them (Deblonde et al., 2011). Ecotoxicological risks associated
48 with their dispersion in receiving surface water have thus already been assessed and proved
49 worldwide (Martín et al., 2012; Mohan and Balakrishnan, 2019; Verlicchi et al., 2012; Yan et al.,
50 2014).

51 Historically, WWTPs have been designed to abate nutrients (nitrogen, phosphorus), particles,
52 and carbonaceous substances (Luo et al., 2014). Removal of EPs through conventional treatment
53 processes (for example, a pre-treatment step, followed by primary decantation and a biological
54 degradation by conventional activated sludge or biofiltration) remains limited (Besha et al., 2017;
55 Kümmerer et al., 2019; Palli et al., 2019). Advanced tertiary treatments (e.g., ozonation, activated
56 carbon adsorption) have been developed to improve water quality by increasing micropollutant
57 removal efficiency (Guillossou et al., 2019; Östman et al., 2019) although some may generate more
58 ecotoxic by-products (Bertanza et al., 2013; Wigh et al., 2016).

59 Thus, a thorough assessment of pollutant removal by WWTPs is necessary to optimize treatment
60 and to avoid the release of ecotoxic compounds into aquatic ecosystems (Luo et al., 2014). Most

61 studies are limited to a single WWTP and a small set of compounds, for example, based on the
62 European priority list (described in the European Water Framework Directive, WFD, 2000), or
63 according to their consumption and PBT (Persistence, Bioaccumulation, Toxicity) criteria (Krauss
64 et al., 2019; Verlicchi et al., 2012; Wiest et al., 2018). Furthermore, as chemical concentrations and
65 loads in influents and effluents are largely influenced by sewershed specificities (Krauss et al., 2019)
66 and WWTP treatments, it is also necessary to study a set of WWTPs with different processes to
67 obtain a more exhaustive view of micropollutant removal.

68 Moreover, tens of thousands of chemicals are registered for commercial use in Europe.
69 Monitoring of small sets of micropollutants can overlook highly ecotoxic substances and lead to a
70 bias in the final risk assessment for aquatic organisms. Analytical methods for EPs that are more
71 comprehensive than the routinely used targeted methods are needed (Hug et al., 2014). In this
72 context, high-resolution mass spectrometry is a promising tool that makes it possible to progress
73 from the screening of one hundred to several thousand analytes (Brack et al., 2019). It is increasingly
74 used to carry out the so-called "suspect screening" chemical analysis (Pinasseau et al., 2019;
75 Ccanccapa et al. 2019; Wang et al., 2019). This kind of screening is based on the comparison of
76 molecular characteristics of unknown components detected in the sample with databases of suspect
77 compounds. The correspondence between these characteristics allows the identification of the
78 compounds present. This approach has been developed and applied to identify different families of
79 EPs such as pharmaceuticals, pesticides, surfactants, industrial chemicals (e.g. chemical synthesis
80 intermediates, additives) and their degradation products/metabolites in wastewaters (Deeb et al.,
81 2017; Gros et al., 2017; Hug et al., 2014; Singer et al., 2016; Wang et al., 2019). This strategy was
82 also applied to evaluate the efficiency of WWTP treatments to remove micropollutants, but only
83 based on the comparison of relative peak areas between the WWTP treated and untreated effluents
84 (Deeb et al., 2017; Wang et al., 2019). The qualitative data did not allow the calculation of precise
85 removals, given the differences in matrix complexity of the two types of water. The combination of
86 suspect screening with confirmation and quantification of identified compounds using analytical
87 standards could give a more exhaustive and comprehensive WWTP efficiency assessment, and load
88 emission evaluation in receiving waters. To our knowledge, up to now, this strategy has only been

89 used in the work published by Gros et al (2017) on grab samples of four WWTPs in Sweden,
90 analyzing 1300 pesticides, pharmaceuticals, and personal care products (PPCPs), fire retardants
91 (FRs) and polyfluoroalkyl substances (PFASs).

92 Consequently, the main objectives of the present work were to: (1) develop and apply a
93 quantitative suspect screening of pharmaceutical residues and pesticides (~2000 substances) in urban
94 wastewater from ten WWTPs, based on LC-QToF-MS; (2) study the advantages and limits of the
95 suspect screening approach with regard to previous monitoring based on targeted analyses (3) thanks
96 to these data, determine the occurrence in raw and treated WW of the identified compounds,
97 including low studied substances; (4) and finally assess their removal efficiency.

98 2. Materials and Methods

99 2.1. Standards and chemicals

100 Chemical standards (targeted compounds and labelled internal standards) used for
101 confirmation and quantification are given in Table S1. Their purity was up to 99 %. Ultra-pure water
102 (Milli-Q) was supplied from Fischer and methanol from BioSolve (Dieuse, France). Individual stocks
103 of standard solutions were prepared at 800 mg/L in methanol, and internal standards at 250 mg/L.
104 Standard solutions were stored in the dark at $-18\text{ }^{\circ}\text{C}$. Working solutions were prepared in ultra-pure
105 water, stored at $4\text{ }^{\circ}\text{C}$ and renewed monthly.

106 2.2. Studied sites and sampling procedure

107 In the present work, selected WWTPs are located in the highly urbanized Lyon (France) city
108 area and sub-urban municipalities, called “Grand Lyon”. In a previous study, Gosset et al. (2020)
109 identified 33 WWTPs releasing effluents in freshwater creeks in this region. In this study, 10 were
110 selected based on 5 main criteria: variability of pollution sources, large range of flow rates of WWTP
111 influent/effluent and receiving watercourse (Brus an Perrodin, 2017), diversity of WWTP treatments,
112 work on a highly anthropized surrounding region (leading to a potentially high-risk context), and
113 finally accessibility and equipment for sampling and monitoring. Their location and main

114 characteristics (population connected, incoming annual flow rate, treatments) are provided in Figure
115 1 and Table 1, respectively. WWTP daily average incoming flow rates vary from 157 to 215092
116 m³/day, with a fairly good correlation with the incoming pollution load (3025 to 622800 population
117 equivalent (PE)). Only WWTP 3 collects exclusively WW from an industrial area. All the others
118 receive a variable proportion of industrial effluents, between 0.11 and 32.11 %. Regarding WWTP
119 7, 8, 9 and 10, hospital effluents are also connected to the municipal network. All WWTPs are
120 equipped with three pretreatment systems: a screening, a grit chamber and a grease remover. Three
121 main primary treatments (coagulation-flocculation, sedimentation tank, buffer tank) and three
122 secondary treatments (activated sludges, biofilter, radial flow fluidized filter) are employed, in
123 function of the WWTP. Finally, an advanced tertiary treatment based on a biofiltration (Biostyr®) is
124 implemented in WWTP 10, to reduce suspended solids, carbon and nitrogen pollution.

125 Influent and effluent WW were sampled in May, October/November and December 2019,
126 to take into account the temporal variability of micropollutant discharges and climatic changes during
127 the year. These three sampling periods are referred to as C1, C2 and C3 throughout the article. Two
128 of them were carried out in dry weather conditions (C1 and C3), and one (C2) was performed in low
129 wet weather conditions (≤ 2.3 mm rainfall). As it was not possible to carry out all samplings on the
130 same day, they were carried out over a period of less than 10 days. Influent samples were collected at the
131 inlet of the treatment plant, at the pretreatment inlet or outlet, depending on WWTP (see Table 1).
132 Effluents were obtained after secondary treatment, except WWTP 10 for which there is a tertiary
133 treatment. Composite 24-h samples (starting and ending at 8 a.m.) according to the flow rate were
134 collected with the same sampling strategy for all WWTPs to ensure representative sampling. WW
135 was sampled using refrigerated automatic samplers with high-density polyethylene containers. Just
136 after sampling, 1 L of each influent/effluent was directly transferred in a 1-L brown glass bottle for
137 EP analyses. Three 250-mL brown glass bottles were also filled for conventional physico-chemical
138 analyses. Then, they were transported to the laboratory in an icebox (dark conditions) and treated for
139 chemical analyses within the 8 following hours.

140
141 2.3. Conventional physico-chemical analyses

142 Conventional physico-chemical parameters (such as pH, conductivity, Total Suspended Solids
143 (TSS), Chemical Oxygen Demand (COD)) and anion/cation concentrations (Na^+ , NH_4^+ , K^+ , Mg^{2+} ,
144 Ca^{2+} , Cl^- , NO_2^- , PO_4^{3-} , NO_3^{2-} , SO_4^{2-}) were quantified according to European standards, as described
145 by Perrodin et al. (2016). Anion/cation analyses were performed after filtering the samples through
146 $0.45\ \mu\text{m}$ (dissolved fraction) while the other parameters were measured on the whole effluents.

147 2.4. Extraction and analysis of EPs

148 2.4.1. Sample preparation and extraction

149 Sample preparation and extraction were conducted based on the method described in Wiest
150 et al. (2018), used for targeted analysis. After a filtration on $0.7\ \mu\text{m}$ glass fiber filters with a filtration
151 System (IT30 142 HW) from Millipore (Molsheim, France), 1 mol/L citric acid solution was added,
152 and 1200/500 μL of a 2 mg/L solution of 20 deuterated internal standards were diluted into 600/250
153 mL of the sample, for effluent/influent respectively. Samples were passed through an automated
154 Solid Phase Extraction (SPE) system (AutoTrace™ 280, from Thermo Fisher®, Roissy, France) in
155 duplicates, using Oasis HLB™ cartridges (6 mL, 150 mg) from Waters® (Guyancourt, France). 250
156 mL/100 mL of filtered WWTP effluents/influents were loaded. Then, cartridges were rinsed with
157 ultrapure water, dried with nitrogen and eluted with methanol. Eluates were dried under nitrogen (at
158 $40\ ^\circ\text{C}$) and samples stored at $-18\ ^\circ\text{C}$. Just before injection, samples were suspended in 1 mL of 90/10
159 ultrapure water/methanol.

160 2.4.2. LC-QToF-MS suspect screening and quantification

161 The general analytical strategy is presented in Figure 2. It comprises suspect screening,
162 confirmation and quantification of EPs by Liquid Chromatography coupled with High Resolution
163 Mass Spectrometry. Samples from May 2019 (C1) were used to carry out the suspect screening
164 analysis to identify and confirm compounds. Then, confirmed substances were quantified in all WW
165 samples (C1, C2, and C3).

166 The suspect screening analysis was done on the first extract of C1 following the protocol
167 derived from Pinasseau et al. (2019). Separation and detection were performed using an Ultimate

168 3000 Ultra High Performance Liquid Chromatography (UHPLC) system from Thermo Scientific®
169 (MA, USA) coupled with a Quadrupole Time of Flight mass spectrometer from Bruker Daltonics®
170 Maxis Plus. Analyses were carried out in reverse phase (elution gradient) employing an Acclaim
171 RSLC 120 C18 column (2.2 μm , 100 x 2.1 mm, Thermo Scientific®), protected with a KrudKatcher
172 Ultra In-Line Filter guard column from Phenomenex (Torrence, CA, USA) and heated at 30 °C. The
173 injected volume was 5 μL . Mobile phases consisted of: an aqueous phase (90%/10% ultrapure
174 water/methanol mixture with 5mM ammonium formate and 0.01% formic acid) and an organic phase
175 (methanol with 5mM ammonium formate and 0.01% formic acid). More details on gradient elution
176 and mass spectrometer calibration are available in Pinasseau et al. 2019. For quality assurance and
177 quality control (QA/QC), several laboratory control samples were performed. The accuracy of the
178 mass detector was checked at the start of each cycle and recalibrated if the mass error was more than
179 0.5 ppm. Every 12 injections, a quality control was injected to verify sensitivity and retention times
180 during data acquisition. A mixture of 10 μl of each extract was prepared and spiked to 500 $\mu\text{g/L}$ with
181 a standard solution of 53 compounds (Table S2). These compounds were also used to adjust retention
182 times in the database. Background signals were identified by analysis of blanks (solvent, procedural,
183 and trip blank). Solvent blanks were also injected to monitor column carryover. All extracts were
184 analyzed in positive electrospray ionization with the following settings: capillary voltage of 3600 V,
185 end plate offset of 500 V, nebulizer pressure of 3 bar (N_2), drying gas of 9 L/min (N_2), and drying
186 temperature of 200 °C. The analysis was performed in broadband Collision Induced Dissociation
187 acquisition mode over the mass range of 80-1000 Da with a scan rate of 2 Hz at 40eV. With this Data
188 Independent Acquisition mode (DIA), all compounds are fragmented in the collision cell, without
189 prior ion selection. Data were acquired with OtofControl 4.1 and Hystar 4.1, Bruker Daltonics®
190 software and processed using TASQ (Target Analysis for Screening and Quantitation) software
191 (version 1.4, Bruker Daltonics®).

192 All detected signals, couples of exact mass and retention time (m/z ; t_R), were compared with
193 two databases: PesticideScreener 2.1 and ToxScreener 2.1 (Bruker Daltonics®). These databases
194 contain exact masses, retention time, isotope pattern and fragments of 1200 pesticides and 800
195 pharmaceutical compounds, respectively. To perform the suspect screening, tolerances on

196 identification criteria (exact mass, retention time, isotope pattern and fragments) were determined in
197 relation to those present in the databases. The filtering strategy of the substances identified by the
198 software was already described in Pinasseau et al. 2019. Briefly, for each identified substance and
199 each identification criteria, a score, high [H], medium [M] or low [L], was determined as follow:
200 $\Delta m/z$ (mDa) <1.5 [H], between 1.6 and 2.5 [M]; > 2.5 [L]; Δt_R (min) \pm 0.25 [H], \pm 0.40 [M], \pm 0.50
201 [L]; mSigma (correlation between the isotope pattern of the expected spectra and the experimental
202 spectra) \leq 25 [H], between 25 and 60 [M] > 60 [L]. And the last criteria was based on the detection
203 (S/N >3) of a minimum of 50% of the fragments with tolerance on exact mass precision $\Delta m/z$ < 20
204 ppm. Only compounds for which the scores of the three criteria were high ([H]) and 50% of the
205 fragments were detected were considered for confirmation, leading to a list of 41 compounds.

206 After the supposed identification, to confirm the suspected features, C1 sample extracts were
207 further spiked with analytical standards of the suspected compounds and were injected with the
208 unspiked C1 sample extracts on the same apparatus and in the same analytical conditions as for
209 suspect screening. Compounds were spiked in the final extract of samples at concentrations between
210 100 and 500 $\mu\text{g/L}$, depending of the sensitivity of the analyte. Fragmentation in Data Dependent
211 Acquisition mode (DDA) using a selection of the exact mass of the suspected compounds. Then, the
212 Extracted Ion Chromatogram (EIC) and the MS/MS spectra of the suspected compounds for spiked
213 and unspiked sample extracts were compared (see an example in Figure S1). In some cases, initial
214 spiked concentration was not enough and spiked extracts with higher concentrations were re-injected
215 until enough sensitivity was obtained to compare spiked and unspiked spectra. The tolerance on the
216 identification criteria were the same as in the suspect screening. If needed, detected fragments were
217 further checked using MassBank. Confirmed substances and their monoisotopic masses and retention
218 times are reported in Table S3.

219 Finally, quantification by internal standard calibration was performed in DIA mode, on the
220 second extract of C1, and on the C2 and C3 extracts, using 20 internal standards. Method limits of
221 quantification (LOQ) for influent and effluent WW, as well as internal standards used for
222 quantification, are summarized in Table S4. LOQ was the lowest concentration for which all the
223 identification criteria were respected and the accuracy was higher than 80%. Lower LOQ were

224 obtained regarding WWTP 3, because its WW was less complex, leading to lower matrix effects.
225 LOQ for this WWTP are also reported in Table S4.

226 2.4.3 LC-MS/MS confirmation

227 Due to the lack of sensitivity for some fragments, eight drugs were difficult to confirm by
228 LC-QToF MS, especially in influent WW: amantadine, gabapentin, sulfamethoxazole, ketoprofen,
229 oxazepam, fluconazole, celiprolol and rosuvastatin (see section 3.2). For these substances, LC-
230 MS/MS analysis was performed only for confirmation, using the following procedure.
231 Chromatographic separation was carried out with an H-Class liquid chromatograph system
232 (Waters®, Milford, MA, USA), using a Kinetex C18 column (50 mm×2.1 mm i.d., 2.6 μm), protected
233 with a KrudKatcher Ultra In-Line Filter guard column from Phenomenex® (Torrence, CA, USA).
234 The column oven temperature was set at 40 °C. Mobile phases consist in water with 0.1 % formic
235 acid and methanol. Flow rate was 0.45 mL/min and the sample volume injected was 2 μL.

236 The LC instrument was coupled to a Xevo TQ-S (Waters®) triple quadrupole mass
237 spectrometer equipped with an electrospray ion source operated in positive mode. Analysis of the
238 target compounds was achieved in Multiple Reaction Monitoring (MRM) mode. Two or three MRM
239 transitions were monitored for each targeted compound. Retention time and MRM ratio were used
240 to confirm the identification of the substance in the samples (Table S5). All data were acquired and
241 processed using Masslynx 4.1 software.

242 2.5. Pollutant mass loads and removal assessment

243 Daily pharmaceutical and pesticide mass loads were calculated using their concentrations in
244 the influent or effluent, and the associated wastewater flow rate at the inlet or outlet, employing the
245 following equation (1):

$$246 \quad DML_x = \frac{Conc_x \times (FR \times 1000)}{10^9}$$

247 (1)

248 Where DML_x is the daily mass load of the pollutant x in the influent or effluent, in g/day; $Conc_x$ is
249 the concentration of the pollutant x in the raw or treated WW, in ng/L; and FR is the flow rate at the
250 inlet or outlet in m^3/day .

251 Finally, the removal rate for each WWTP, pollutant and period was obtained by the
252 equation (2):

$$253 \quad RR = \left(1 - \frac{DML_{effluent}}{DML_{influent}}\right) \times 100$$

254 (2)

255 Where RR is the removal rate in %; $DML_{effluent}$, the daily mass load in the effluent, in g/day;
256 $DML_{influent}$, the daily mass load in the influent, in g/day. Calculating RR when EPs are not detected
257 or quantified can lead to errors. Consequently, in case of EPs below their respective LOQ (<LOQ)
258 or non-detection (n.d.) into effluent samples, their concentrations were respectively fixed at $LOQ/2$
259 and 0 ng/L in order to calculate removal efficiencies. On the contrary, when one of these two cases
260 appeared in the influent samples, the removal calculation was not carried out. Finally, when EPs were
261 below their LOQ in both WWTP's inlet and outlet samples, they were not calculated.

262 3. Results and discussion

263 3.1. Conventional physico-chemical parameters

264 In order to ensure the correct performance of the WWTPs, and so that the results of the study
265 can be compared with the scientific literature, several conventional physico-chemical parameters
266 were monitored during the three campaigns. Their minimum, median, mean, maximum values and
267 frequency of detection for all 30 samples are reported in Table 2. A similar range of values was
268 observed for the different influent and effluent parameters in various studies performed on French
269 WWTPs (Deycard et al., 2014; Fulazzaky et al., 2015; Gasperi et al., 2012; Pasquini et al., 2014;
270 Wiest et al., 2018). Total suspended solids (Mean = 270.80 mg/L) and chemical oxygen demand
271 (Mean = 588.37 mg/L) are relatively high and typical of highly urbanized territories. Effluent
272 parameters, and in particular TSS and COD, of the 10 WWTPs respect the stricter regulations of the

273 French Order (N°223 09/23/2017) on collective sewerage systems: values respectively below 35
274 mg/L and 125 mg O₂/L (Pasquini et al., 2014). Moreover, the mean removal rate by WWTPs for
275 these two parameters is respectively 94.47 % and 92.37 %, while this Order imposes an efficiency
276 of up to 90 % and 75 % for the largest WWTPs (BOD₅ > 1,2 kg/day). These values show the normal
277 and efficient functioning of the studied WWTPs during the three sampling campaigns. Accordingly,
278 the removal rates for the various detected EPs can be considered as typical and representative of the
279 10 WWTP's efficiency (Pasquini et al., 2014).

280 3.2. Advantages and limits of the quantitative suspect-screening approach

281 LC-QToF-MS analyses performed in this study are summarized in Figure 2. In order to be
282 sure to publish reliable data and to avoid any false positive, we chose to study only EPs that were
283 confirmed by comparison with their corresponding analytical standard, that is with a confidence of
284 level 1 according to Schymanski et al. (2014). Thanks to this strategy, 41 EPs were ultimately
285 confirmed and quantified by internal standard calibration (see Tables S2 and S3). The same
286 identification criteria were used for suspect screening and quantification. During the quantification
287 step, strictly following these criteria, eight **compounds** (amantadine, gabapentin, sulfamethoxazole,
288 ketoprofen, oxazepam, fluconazole, celirolol and rosuvastatin) were not successfully identified in
289 raw WW, whereas they were identified in the corresponding treated WW. The unfulfilled criteria
290 was the detection of fragments, due to a high level of noise in chromatograms of raw WW. An
291 example of the obtained chromatograms for fluconazole is presented in Figure S2. For these
292 substances, an additional LC-MS/MS analysis (see Section 2.4.3) of the sample extract was
293 performed, which allowed the confirmation of the presence of these compounds in raw WW.

294 Among the 41 EPs identified in the raw and treated WW samples, 37 pharmaceuticals and 4
295 pesticides (DEET, diuron, fluopyram and terbutryn) were observed. To illustrate the usefulness of
296 suspect screening to detect **substances** that have been poorly/not studied in the literature, Figure 3
297 represents the number of scientific studies with a topic in relation to each EP detected here and
298 wastewater or specifically urban/municipal wastewater (Web of Knowledge search, last access: 04-
299 01-2020). Among the EPs, some of them, such as diclofenac (a nonsteroidal anti-inflammatory drug),

300 carbamazepine (anticonvulsant), sulfamethoxazole or trimethoprim (antibiotics) have already been
301 widely reported and quantified in influents and effluents, and reviewed for many WWTPs worldwide
302 (Couto et al., 2019; Deblonde et al., 2011; Luo et al., 2014). The name of each of them appears in
303 more than 700 studies (Figure 3). On the contrary, this graph clearly highlights a low number of
304 studies (<10) for 9 of them considering all types of wastewaters: trospium (overactive bladder
305 treatment), milnacipran (serotonin–norepinephrine reuptake inhibitor), tiapride (neuroleptic),
306 fluopyram (fungicide), flecainide (antiarrhythmic agent), methocarbamol (muscle relaxant),
307 celiprolol (beta blocker), disopyramide (antiarrhythmic drug) and sitagliptin (antidiabetic drug). For
308 specific municipal/urban wastewater, 19 of the EPs (46%) can be considered as poorly
309 investigated/evoked. Finally, no previous studies were found for milnacipran. This shows that
310 suspect screening not only allows to detect non-targeted substances, as in Singer et al. (2016), but
311 also to identify not yet unsuspected or investigated ones in wastewater. Hug et al. (2014) reached to
312 a similar conclusion, detecting six EPs never reported as pollutants previously, by suspect-screening
313 in urban wastewater effluents. Additionally, some recent studies have also drawn the same findings
314 for other urban discharges, such as stormwater or highway runoffs (Du et al., 2017; Pinasseau et al.,
315 2019). As a result, it is clear that the scientific community is still far from having identified all the
316 pollution linked to wastewater and therefore the associated environmental risks. The suspect-
317 screening approach developed in this work is an efficient tool in the attempt to fill this knowledge
318 gap.

319 3.3. Occurrence and concentrations of emerging pollutants in raw wastewaters

320 In order to study the contamination of raw wastewater by the 41 EPs, to compare it with
321 other studies/countries and to discuss their potential sources, their concentrations and occurrences
322 were monitored in influents of all treatment plants over the three sampling periods. The box plot and
323 data synthesis of EP concentrations are presented in Figure 4 and Supplementary Table S6. Among
324 the 37 pharmaceutical residues identified, 12 (atenolol, benzoylecgonine, carbamazepine, cetirizine,
325 codeine, fexofenadine, flecainide, irbesartan, sitagliptin, trimethoprim, valsartan, venlafaxine) were
326 detected in all samples, 29 had a detection frequency greater than or equal to 90% and 36 exceeded

327 70%. There is therefore a widespread contamination of the influent samples by pharmaceutical
328 residues. Only one analyte, the antidepressant milnacipran, was poorly detected (36.67%). The
329 highest median concentrations were found for gabapentin (5068.81 ng/L), valsartan (2823.46 ng/L),
330 sitagliptin (2298.62 ng/L) and naproxen (1941.76 ng/L). On the contrary lower ones were determined
331 for cetirizine (113.82 ng/L), trospium (92.99 ng/L), disopyramide (46.42 ng/L) and clopidogrel
332 (27.68 ng/L). In 2012, Verlicchi et al. carried out a review mostly of European studies about the
333 contamination of wastewater by 118 pharmaceuticals, and in particular 13 detected here. The
334 concentration ranges for atenolol, bisoprolol, carbamazepine, celiprolol, codeine, diclofenac,
335 gabapentin, ketoprofen, naproxen, sulfamethoxazole, trimethoprim and valsartan were similar to
336 ours, although there were some variations in the average concentrations (e.g. lower in the present
337 case for trimethoprim and carbamazepine; higher for celiprolol). More recently, three studies (Burns
338 et al., 2018; Gurke et al., 2015; Saussereau et al., 2013) provided complementary data about
339 contamination of English, German, and French WWTP influents by cetirizine, citalopram,
340 disopyramide, fexofenadine, flecainide, irbesartan, lidocaine, oxazepam, sitagliptin, telmisartan,
341 venlafaxine and verapamil. The same range of values held for all EPs, except for valsartan (mean
342 conc.: 29685 ng/L; Gurk et al., 2015), oxazepam and sitagliptin (mean conc.: 22.7-37.2 ng/L and
343 187-742 ng/L respectively; Burns et al., 2018). Average valsartan concentrations are 10 times lower
344 in our study, while they are approximately 100 and 10 times higher for oxazepam and sitagliptin,
345 respectively. Benzoylcegonine was the only detected metabolite of an illicit drug, cocaine (but also
346 used in a drug for muscle pain). Nefau et al. (2013) performed a complete wastewater contamination
347 study for 25 WWTPs across France, and observed a detection frequency above 80 % (100 % here),
348 with concentrations varying between 21 and 3050 ng/L, which is in accordance with the present study
349 (48.8 - 2140.63 ng/L). Finally, as already expressed in part 3.2, no comparison with literature was
350 possible for some EPs, such as methocarbamol, milnacipran, tiapride and trospium, as to our
351 knowledge no data on urban raw WW were reported in any study before the present one.

352 Among the detected pharmaceutical residues, only 5 of them (atorvastatin (med. conc.: 207
353 ng/L), bisoprolol (389.28 ng/L), codeine (617 ng/L), diclofenac (1115.7 ng/L) and lidocaine (364.61
354 ng/L)) are in the list of the 30 most sold (in quantity) in French cities (ANSM, 2014). Moreover,

355 Figure 4 shows that these compounds do not present concentrations among the highest of the 37
356 pharmaceutical residues. Several factors may explain this statement:

357 - The difference in the dosage of active substances according to drug formulations: some
358 drugs are less prescribed but contain higher doses of active substance, such as gabapentin (100 to
359 800 mg tablets), valsartan (40 to 160 mg) or naproxen (550 mg), compared to bisoprolol (1.25 to 10
360 mg) and atorvastatin (10 to 80 mg) (Vidal, 2020).

361 - The metabolization of drugs in the human body prior to their excretion, creating metabolites
362 that are not in the suspect screening database (Miège et al., 2006).

363 - The differences in capability of some pharmaceuticals to be adsorbed on wastewater
364 particles (sewage sludges/biosolids) (Archer et al., 2017).

365 - The differences in the biodegradation of pharmaceutical compounds in the sewers before
366 the WWTP inlets. Laquaz et al. (2020) observed for example on a 2.7 km long sewer some decreases
367 (or increases depending on the sampling campaign) of diclofenac, atenolol and ketoprofen
368 concentrations between upstream and downstream sites. In the present case, more than 3200 km of
369 sewer pipes convey the urban WW to the 10 WWTPs of the territory.

370 - The influence of demographic and socio-economic parameters (e.g. mean age, mean salary,
371 presence of hospitals or factories) of the 10 WWTP sewersheds. These factors influence drug
372 consumption, and then the mass load emitted (Choi et al., 2019), the final concentrations in the
373 various sewers, and finally, the median concentrations presented here.

374 Concerning pesticides, three of them were highly detected into the influents ($\geq 80\%$): diuron
375 (med. Conc.= 19.46 ng/L), terbutryn (23.99 ng/L) and DEET (295.07 ng/L). These results are in
376 accordance with European scientific literature. For example, Gasperi et al. (2008) detected diuron in
377 all their wastewater samples from Paris, France, with a concentration range of 0.03-0.47 $\mu\text{g/L}$
378 (present case: $< \text{LOQ} - 1.43 \mu\text{g/L}$). Conversely, they did not detect terbutryn, which is in
379 contradiction with this study, and can be explained by a LOQ higher (60 ng/L) than the current one.
380 Moreover, Köck-Schulmeyer et al. (2013) also observed a diuron median concentration of 42.2
381 ng/L (detection frequency: 88%) in the influent of Spanish WWTPs. The omnipresence of these two
382 herbicides in urban wastewater can be surprising because they have been banned in French

383 agriculture since 2003 (terbutryn) and 2008 (diuron). Their current source mainly lies in their use as
384 algicides in surface coatings (paints and renders) of walls and roofs of urban buildings (Bollmann et
385 al., 2014; Gros et al., 2017; Tlili et al., 2017). Conversely, the high detection frequency (93.3%) of
386 DEET mosquito repellent is consistent with the literature, as it is the most used mosquitoes repellent
387 in the world, and one of the most commonly detected organic contaminants in aqueous matrices (e.g.
388 wastewater and surface water) (Merel and Snyder, 2016). Moreover, associated concentrations in
389 influents are in the wide range of values observed in Europe and Worldwide (Dos Santos et al., 2019;
390 Tran et al., 2018). Finally, fluopyram was detected in only 6 raw WW samples (WWTPs 3, 8 and 10;
391 detection freq. = 20 %), with a high median concentration (529.36 ng/L). The presence of fluopyram
392 in urban wastewater is surprising because of its main use as a fungicide in agriculture. Its detection
393 could be explained by the presence of cereal crops in the sewershed areas of WWTPs 8 and 10, and
394 the presence of a pesticide factory in that of WWTP 3 (entirely industrial). Nevertheless, the current
395 results are consistent with a recent study that detected fluopyram in urban stormwater from an
396 industrial area (containing several small crops) in the same conurbation (Pinasseau et al., 2019).

397 3.4 Overall removal assessment of emerging pollutants by WWTP treatments

398 To assess the removal of EPs and the potential correlation with their structures and physico-
399 chemical properties, removal rates (RR) of the 41 EPs were calculated, as detailed in section 2.5.
400 Figure 5 represents the removal efficiency of each identified pollutant for all WWTP and sampling
401 campaigns. All the associated raw data are provided in Supplementary data. The overall removal
402 corresponds to the loss of EP parent compounds from the aqueous phase of WWs (Luo et al., 2014).
403 A strong variation was observed between the 41 compounds (from -96.7 % median removal rate
404 (MRR) for clopidogrel to 92.9 % for benzoylcgonine), including between substances of the same
405 therapeutic family (-9.5 % and 59.2 % for irbesartan and valsartan, respectively – 2 antihypertensive
406 drugs), as already reported (Campo et al., 2013; Gurke et al., 2015; Tran et al., 2018). Four different
407 MRR trends, following the classification of Tsui et al. (2014), were observed depending on the EP
408 (Table 3):

409 (1) An important/high median removal rate (MRR > 70 %), for 7 EPs: benzoylecgonine,
410 telmisartan, naproxen, gabapentin, acebutolol, ketoprofen and fexofenadine. Two compounds still
411 sometimes present low or negative elimination rates (gabapentin and benzoylecgonine). The best
412 removal rates were obtained for benzoylecgonine (a metabolite of cocaine, which is also used as
413 analgesic) and telmisartan (MRR: 92.9 and 90.7 %, respectively). Acebutolol, fexofenadine and
414 telmisartan presented removal rates higher than those reported in the literature, whereas the others
415 exhibited values in accordance with previous studies on conventional (secondary treatment : mainly
416 activated sludges or membrane biological reactors) WWTPs (Table 3 - Archer et al., 2017; Burns et
417 al., 2018; Couto et al., 2019; Deblonde et al., 2011; Golovko et al., 2014; Gurke et al., 2015; Luo et
418 al., 2014; Repice et al., 2013; Santos et al., 2013; Saussereau et al., 2013; Tran et al., 2018; Yadav et
419 al., 2019). The main mechanisms for the removal of pollutants are biotransformation/biodegradation,
420 volatilization, and adsorption on sludge. The volatilization of EPs (in particular pharmaceuticals)
421 appears limited during WWTPs treatments (Besha et al., 2017; Luo et al., 2014; Verlicchi et al.,
422 2012). Bacterial bioavailability, potential of biodegradation, and adsorption phenomena are directly
423 linked to the hydrophobicity/hydrophilicity of EPs (reflected by K_{ow}) (Cirja et al., 2008). For
424 compounds with $\log K_{ow} < 2.5$, adsorption is not expected, for those with $\log K_{ow}$ between 2.5 and 4
425 moderate sorption is intended, and for EPs with $\log K_{ow}$ up to 4, a high sorption potential exists
426 (Rogers, 1996; Cirja et al., 2008; Luo et al., 2014). In our case, all EPs present a $\log K_{ow}$ below 4
427 (2.71; 1.794; 1.391; 1.95; 1.651 and 3.529 respectively for benzoylecgonine, naproxen, gabapentin,
428 acebutolol, ketoprofen, and fexofenadine), except for telmisartan (5.046) (INERIS, 2020;
429 ChemSpider, 2020). Its high sorption potential, explaining the high removal values, has already been
430 observed recently by Iranzo et al. (2018), who quantified very high concentrations of telmisartan in
431 Spanish WWTP sewage sludge (> mg/kg). On the contrary, efficient removal of ketoprofen and
432 naproxen, for example, has already been observed (Jelic et al., 2011), unrelated to adsorption in
433 sludge. Nevertheless, caution must be exercised with regard to the high disposal values observed, as
434 the (bio-)degradation by-products were not quantified in this study (Barbieri et al., 2012). The pH
435 also plays an important role in removal as it influences the molecular charge, and thus the capacity

436 of an EP to be adsorbed on sludge (Verlicchi et al., 2012). In our case ($7.40 < \text{pH} < 8.10$), acebutolol
437 is positively charged, which could also partially explain its efficient removal during treatment.

438 (2) A moderate median removal rate ($30 \% < \text{MRR} < 70 \%$), for 13 EPs: rosuvastatin (67.3
439 %), atenolol, DEET, valsartan, atorvastatin, sulfamethoxazole, verapamil, citalopram, trospium,
440 trimethoprim, sitagliptin, codeine and celiprolol (30.69 %). Concerning statins, rosuvastatin removal
441 rates (MRR: 67.3 %; mean removal: 64.5 %) were in accordance with Golovko et al. (2014), which
442 observed a mean removal rate of 68 % in some urban WWTP from the Czech Republic. Conversely,
443 atorvastatin was not as efficiently removed (MRR/mean removal of 56.5 and 55.6 %, respectively)
444 than in previous studies ($> 66.7 \%$) (Archer et al., 2017; Couto et al., 2019; Golovko et al., 2014).
445 The antihypertensive compounds, atenolol, celiprolol and verapamil were eliminated in the range of
446 values observed in previous studies (Table 3), but with high variability (See Figure 5).

447 (3) A poor median removal rate ($0 \% < \text{MRR} < 30 \%$), for 17 EPs: bisoprolol (29.08 %),
448 methocarbamol, amantadine, fluopyram, cetirizine, amisulpride, oxazepam, milnacipran, flecainide,
449 diclofenac, EDDP, carbamazepine, venlafaxine, terbutryn, disopyramide, lidocaine and fluconazole
450 (2.5 %). The observed values are also generally in agreement with the literature ($< 30 \%$), as a large
451 variability in removal rates has been previously observed in conventional WWTPs (Table 3). For
452 example, carbamazepine (MRR: 15.75%; mean removal: 11.80 %) was eliminated with rates ranging
453 from -12 % to 94.9 % depending on the country and the WWTP. Most of moderately and poorly
454 removed EPs have $\log K_{ow} < 4$, resulting in a partial elimination due more to bad biodegradation than
455 to partial sorption in sludges. Thus, the observed removal rates could have two main explanations:
456 the first is that the wastewater residence time (low Hydraulic Retention Time (HRT) values) was too
457 weak, which would have not allowed complete biodegradation of the substances by the catabolic
458 actions of microbes (Gros et al., 2010; Couto et al., 2019). The second lies in the chemical structure
459 of the EP: esters, nitriles and/or aromatic alcohol functional groups may lead to increase the microbial
460 biodegradability of EPs when iodide, nitro-, azo-, sulfo-, halogen (e.g. chlorine) and/or aromatic
461 amine functional groups would decrease their biodegradability (Besha et al., 2017; Cirja et al., 2008;
462 Zorita et al., 2009). Moreover, linear EPs with short side chains and unsaturated aliphatic structures

463 are more easily biodegraded than long and highly branched side chains EPs, with saturated or
464 polycyclic structures (Luo et al., 2014). Nevertheless, a relationship between chemical structure and
465 removal efficiency is often difficult to demonstrate. In the present case, the complexity of well-
466 removed EPs does not differ drastically from the poorly eliminated ones (e.g., the presence in many
467 of them of several benzene groups). However, it can be observed that some of the poorly removed
468 EPs present one or several aromatic amines (e.g. amantadine, amisulpride) or halogen groups (fluor:
469 flecainide and fluopyram; sulphur: amisulpride and terbutryn; chlorine: amantadine, cetirizine and
470 oxazepam). The medium/low removal rate of diclofenac previously reported (Deblonde et al., 2011;
471 Vieno and Sillanpää, 2014) was also imputed to the presence of 2 chlorine groups (Cirja et al., 2008;
472 Jelic et al., 2011; Kimura et al., 2005).

473 (4) A negative median removal rate ($MRR < 0 \%$), for 4 EPs: clopidogrel (-96.73 %),
474 tiapride, irbesartan and diuron (-7.55 %). These results are consistent with the literature (Table 3 –
475 Sassereau et al., 2013; Santos et al., 2013), except for the pesticide diuron for which one only positive
476 removal has been previously reviewed (26.7–71.9%) (Luo et al., 2014). Negative removal was
477 observed at least once for 33 of 41 identified compounds in the WW. Moreover, for a third of them,
478 a higher mass load into the effluents was observed recursively (more than 5 times). For clopidogrel
479 (an antiaggregant) or tiapride, a positive removal rate was observed only two times. Three main
480 mechanisms can explain the present results: (a) a release/desorption from fecal particles under
481 specific abiotic conditions (Archer et al., 2017); (b) a release from particles broken under the
482 microbial action, as already observed for trimethoprim (Göbel et al., 2007), and finally, (c) a
483 deconjugation during biological processes of glucuronide or sulfate-conjugated pollutant
484 metabolites, as already discussed for some of the EPs of this study (e.g. diclofenac, carbamazepine
485 or venlafaxine) (Archer et al., 2017; Campo et al., 2013; Gurke et al., 2015; Petrie et al., 2015;
486 Verlicchi et al., 2012; Vieno and Sillanpää, 2014; Zorita et al., 2009). Nevertheless, if these general
487 mechanisms are known, their implication in the present results remains impossible to assess as
488 conjugated metabolites, as well as particulate phase and sludge pollutions, were not examined in this
489 study (Gurke et al., 2015; Petrie et al., 2015). Negative removal rates could also be related to a

490 problem of sampling strategy, in particular the collection of 24-hour samples whereas HRT values
491 from wastewater treatment plants may be higher. Problems with sample preservation prior to
492 analysis, or the fact that some samples in this study were collected during low rainfall events, may
493 also be responsible for these negative rates (Köck-Schulmeyer et al., 2013).

494 Finally, no removal rate comparison was possible for 6 EPs (trospium, fluopyram,
495 methocarbamol, milnacipran, amisulpride, and tiapride) as no data were reported in any study to our
496 knowledge. The high variability of removal efficiency observed for EPs can be explained by many
497 factors: the variation of temperature of operation (higher removal rates are expected in summer
498 compared to winter), the redox conditions, the pH, the biomass concentration/population, and the
499 sludge retention time (SRT) and HRT (Gros et al., 2010). In this study, results might not be related
500 to a difference of pH, as it changed poorly among the WWTPs and sampling periods (Ben et al.,
501 2018). Thus, it might be primarily due to the diversity of WWTP treatments and the difference of
502 pollution and efficiencies for the diverse sampling periods (Wiest et al., 2018). In addition, the
503 detection of EPs at concentrations close to their respective LOQ could have led to variability and
504 unreliability of results and associated conclusions (Jelic et al., 2011).

505 3.5 Occurrence, concentrations and hazard related to emerging pollutants in treated wastewaters

506 To investigate the potential contamination of the receiving watercourses, the concentrations
507 and occurrence of the 41 emerging pollutants in the effluents for all WWTPs and sampling periods
508 were studied, and are compiled in Figure 6 and in Supplementary Table S6. Due to their partial
509 removal, each EP was detected at least once in the effluents. All substances were detected in treated
510 effluents with high detection frequency (>70%), except for rosuvastatin (66.67 %), gabapentin (46.67
511 %), milnacipran (36.67 %) and fluopyram (20%, as in raw WW). Eight EPs were detected in all
512 samples (atenolol, carbamazepine, cetirizine, diuron, irbesartan, sitagliptin, trimethoprim,
513 venlafaxine). Despite its good median removal rate (86.33), gabapentin exhibited higher
514 concentration (med.conc.: 3486.31 ng/L), followed by sitagliptin (1598.36 ng/L), valsartan (1574.43
515 ng/L), and irbesartan (1332.83 ng/L). On the contrary, disopyramide (42.2 ng/L) fluopyram (32.1

516 ng/L), diuron (27.09 ng/L) and terbutryn (17.53 ng/L) presented the lowest ones. Concentrations are
517 generally in accordance with data reviewed in the literature (e.g. dos Santo et al., 2019; Luo et al.,
518 2014; Nannou et al., 2020; Tlili et al., 2017; Verlicchi et al., 2012). The significant concentrations of
519 pharmaceutical residues detected in treated WW can be easily explained by a resistance to treatments
520 (e.g. irbesartan) (Gros et al., 2010; Wiest et al., 2018) or to very high raw wastewater concentrations
521 (e.g. gabapentin), for which efficient treatments are not sufficient to decrease significantly the
522 concentrations emitted into the environment. The widespread contamination of diuron and terbutryn
523 in current effluent samples is consistent with the study performed by Tlili et al. (2017) according to
524 which herbicide contamination of effluents from the Swiss WWTPs of the two small rural towns of
525 Steinach and Herisau was not of agricultural origin but was dominated by these two biocides.
526 Compared to raw WW, one study was recently reported the presence of trospium and tiapride in
527 urban effluents of 6 Swiss WWTPs (Singer et al., 2016), with concentrations ranging from less than
528 10 (LOQ) to 74 ng/L and from 8 to 37 ng/L, respectively. Trospium concentrations were in
529 accordance with the present results (range: n.d. – 183.91 ng/L med. conc.: 58.16 ng/L), but lower
530 than those reported here for tiapride (range: n.d. – 1.23 µg/L; med. conc.: 486.53 ng/L). No
531 comparison with literature was possible for some EPs (e.g. methocarbamol, milnacipran, and
532 fluopyram) as no data have been reported on treated wastewaters in any study to our knowledge.

533 Ecotoxicological hazard related to treated WW pollution can be discussed by comparing the
534 median concentration (See Table S6) of EPs in effluents (Measured Environmental Concentration -
535 MEC) with their environmental threshold values (PNEC - Predicted No Effect Concentration) in
536 order to calculate related median hazard quotients ($HQ_{med} = MEC/PNEC$) (Gosset et al., 2017). An
537 HQ_{med} value above 1 implies a significant ecotoxicological hazard for aquatic ecosystems. For
538 example, PNEC values determined for atorvastatin (0.26 ng/L), atenolol (5 ng/L), citalopram (6.35
539 ng/L), diclofenac (20 ng/L) and telmisartan (26 ng/L) by Orias and Perrodin (2013) and Zhou et al.
540 (2019) led us to calculate HQ_{med} values of 358.42, 73.05, 18.28, 39.27 and 3.42, respectively. These
541 significant and high-hazard values are in accordance with recent studies (e.g. Ramírez-Morales et al.,
542 2020) and illustrate that it would be crucial to assess the final ecotoxicological risk associated with

543 the whole set of EPs for the receiving ecosystems in this region, which presents a diversity of
544 exposure conditions (e.g. dilution) in treated WW. This is the subject of the second article in this
545 series (Gosset et al., submitted).

546 4. Conclusion and perspectives for further study

547 This study presents the results of a highly comprehensive analytical methodology, which
548 was successfully developed based on the coupling of a LC-QToF-MS "suspect screening" followed
549 by a targeted quantification of identified EPs. It was applied to raw and treated wastewater from 10
550 wastewater treatment plants in a highly urbanized area. Due to the wide variety of profiles (e.g.
551 sewershed) of the 10 treatment plants, chemical analyses showed wide variability in the
552 concentration of the 41 confirmed EPs in the raw wastewater, and in their removal during treatment.
553 Consequently, efforts (e.g. reduction at source, improvement of treatments) should be made
554 regarding many EPs refractory to WW treatment that are frequently detected in WWTP outfalls (e.g.
555 clopidogrel or venlafaxine). Their concentrations in discharged effluents (median conc. between
556 17.53 and 3486.31 ng/L) could potentially pose a risk to receiving watercourses. The number of
557 valuable data obtained from our study proved the relevance of the suspect screening approach to
558 evaluate wastewater contamination, providing findings about EPs never studied, to our knowledge,
559 in urban influent/effluent (e.g. methocarbamol and milnacipran). Using this methodology on other
560 sources of pollution such as combined sewer overflows, or over several campaigns to assess the
561 seasonal and annual variation would be of great benefit. In parallel, more extensive databases of
562 compounds allowing for the detection of additional pharmaceuticals and pesticides are necessary to
563 improve this strategy. Harmonized guidelines and validated procedures would also be very useful to
564 promote the use of these tools for future research work.

565

566 Acknowledgment

567 This work was supported by the Lyon Urban School, through a funding grant from the French
568 National Research Agency (Programme Investissements d'Avenir (ANR-17-CONV-0004)). This

569 study also received a scientifically, technic and financially support of the French Ministry of Ecology
570 (through the ENTPE), the Greater Lyon and the University Lyon 2.

571 This work was performed within the framework of the EUR H2O'Lyon (ANR-17-EURE-0018) of
572 Université de Lyon (UdL), within the program "Investissements d'Avenir" operated by the French
573 National Research Agency (ANR).

574 References

575 ANSM, 2014. Analyse des ventes de médicaments en France en 2013/Analysis of drug sales in
576 France in 2013. (Last consultation : 10-27-2020). [https://ansm.sante.fr/S-](https://ansm.sante.fr/S-informer/Communiqués-Communiqués-Points-presse/Ventes-de-medicaments-en-France-le-rapport-d-analyse-de-l-annee-2013-Communique#:~:text=Les%20donn%C3%A9es%20pour%202013%20font,euros%20de%20ventes%20aux%20h%C3%B4pitaux)
577 [informer/Communiqués-Communiqués-Points-presse/Ventes-de-medicaments-en-France-le-](https://ansm.sante.fr/S-informer/Communiqués-Communiqués-Points-presse/Ventes-de-medicaments-en-France-le-rapport-d-analyse-de-l-annee-2013-Communique#:~:text=Les%20donn%C3%A9es%20pour%202013%20font,euros%20de%20ventes%20aux%20h%C3%B4pitaux)
578 [rapport-d-analyse-de-l-annee-2013-](https://ansm.sante.fr/S-informer/Communiqués-Communiqués-Points-presse/Ventes-de-medicaments-en-France-le-rapport-d-analyse-de-l-annee-2013-Communique#:~:text=Les%20donn%C3%A9es%20pour%202013%20font,euros%20de%20ventes%20aux%20h%C3%B4pitaux)
579 [Communique#:~:text=Les%20donn%C3%A9es%20pour%202013%20font,euros%20de%20ve-](https://ansm.sante.fr/S-informer/Communiqués-Communiqués-Points-presse/Ventes-de-medicaments-en-France-le-rapport-d-analyse-de-l-annee-2013-Communique#:~:text=Les%20donn%C3%A9es%20pour%202013%20font,euros%20de%20ventes%20aux%20h%C3%B4pitaux)
580 [ntes%20aux%20h%C3%B4pitaux](https://ansm.sante.fr/S-informer/Communiqués-Communiqués-Points-presse/Ventes-de-medicaments-en-France-le-rapport-d-analyse-de-l-annee-2013-Communique#:~:text=Les%20donn%C3%A9es%20pour%202013%20font,euros%20de%20ventes%20aux%20h%C3%B4pitaux)).

581 Archer, E., Petrie, B., Kasprzyk-Hordern, B., Wolfaardt, G. M., 2017. The fate of pharmaceuticals
582 and personal care products (PPCPs), endocrine disrupting contaminants (EDCs), metabolites and
583 illicit drugs in a WWTW and environmental waters. *Chemosphere*, 174, 437-446.

584 Barbieri, M., Carrera, J., Ayora, C., Sanchez-Vila, X., Licha, T., Nödlér, K., Osorio, V., Pérez, S.,
585 Köck-Schulmeyer, M., López de Alda, M., Barceló, D., 2012. Formation of diclofenac and
586 sulfamethoxazole reversible transformation products in aquifer material under denitrifying
587 conditions: batch experiments. *Sci. Total Environ.* 426, 256-263.

588 Ben, W., Zhu, B., Yuan, X., Zhang, Y., Yang, M., Qiang, Z., 2018. Occurrence, removal and risk of
589 organic micropollutants in wastewater treatment plants across China: Comparison of wastewater
590 treatment processes. *Water Res.* 130, 38-46.

591 Bertanza, G., Papa, M., Pedrazzani, R., Repice, C., Mazzoleni, G., Steimberg, N., Feretti, D., Ceretti,
592 E., Zerbini, I., 2013. EDCs, estrogenicity and genotoxicity reduction in a mixed (domestic+textile)
593 secondary effluent by means of ozonation: A full-scale experience. *Sci. Total Environ.* 458-460,
594 160-168.

595 Besha, A. T., Gebreyohannes, A. Y., Tufa, R. A., Bekele, D. N., Curcio, E., Giorno, L., 2017.
596 Removal of emerging micropollutants by activated sludge process and membrane bioreactors and
597 the effects of micropollutants on membrane fouling: A review. *J. Environ. Chem. Eng.* 5(3), 2395-
598 2414.

599 Bollmann, U. E., Tang, C., Eriksson, E., Jönsson, K., Vollertsen, J., Bester, K., 2014. Biocides in
600 urban wastewater treatment plant influent at dry and wet weather: Concentrations, mass flows and
601 possible sources. *Water Res.* 60, 64-74.

602 Brack, W., Hollender, J., de Alda, M.L., Mueller, C., Schulze, T., Schymanski, E., Slobodnik, J.,
603 Krauss, M., 2019. High-resolution mass spectrometry to complement monitoring and track emerging
604 chemicals and pollution trends in European water resources. *Env. Sci. Eur.* 31.

605 Brus, A., Perrodin, Y., 2017. Identification, assessment and prioritization of ecotoxicological risks
606 on the scale of a territory: Application to WWTP discharges in a geographical area located in
607 northeast Lyon, France. *Chemosphere* 189, 340-348.

608 Burns, E. E., Carter, L. J., Kolpin, D. W., Thomas-Oates, J., Boxall, A. B., 2018. Temporal and
609 spatial variation in pharmaceutical concentrations in an urban river system. *Water Res.* 137, 72-85.

610 Campo, J., Masiá, A., Blasco, C., Picó, Y., 2013. Occurrence and removal efficiency of pesticides in
611 sewage treatment plants of four Mediterranean River Basins. *J. Hazard. Mater.* 263, 146-157.

612 Ccancapa-Cartagena, A., Pico, Y., Ortiz, X., Reiner, E.J., 2019. Suspect, non-target and target
613 screening of emerging pollutants using data independent acquisition: Assessment of a Mediterranean
614 River basin. *Sci. Total Environ.* 687, 355-368.

615 ChemSpider, 2020. Chemical database of the Royal Society of Chemistry.
616 <http://www.chemspider.com/> (Last consultation : 11-03-2020)

617 Choi, P. M., Tschärke, B., Samanipour, S., Hall, W. D., Gartner, C. E., Mueller, J. F., O'Brien, J. W.
618 2019. Social, demographic, and economic correlates of food and chemical consumption measured
619 by wastewater-based epidemiology. *PNAS* 116(43), 21864-21873.

620 Cirja, M., Ivashechkin, P., Schäffer, A., Corvini, P. F., 2008. Factors affecting the removal of organic
621 micropollutants from wastewater in conventional treatment plants (CTP) and membrane bioreactors
622 (MBR). *Rev. Environ. Sci. Biotechnol.* 7(1), 61-78.

623 Couto, C. F., Lange, L. C., Amaral, M. C., 2019. Occurrence, fate and removal of pharmaceutically
624 active compounds (PhACs) in water and wastewater treatment plants—A review. *J. Water*
625 *Proc. engineering* 32, 100927.

626 Deblonde, T., Cossu-Leguille, C., Hartemann, P., 2011. Emerging pollutants in wastewater: a review
627 of the literature. *Int. J. Hyg. Environ. Health* 214(6), 442-448.

628 Deeb, A., Stephan, S., Schmitz, O. J., Schmidt, T. C., 2017. Suspect screening of micropollutants
629 and their transformation products in advanced wastewater treatment. *Sci. Total Environ.* 601, 1247-
630 1253.

631 Deycard, V. N., Schäfer, J., Blanc, G., Coynel, A., Petit, J. C., Lanceleur, L., Dutruch, L., Bossy, C.,
632 Ventura, A., 2014. Contributions and potential impacts of seven priority substances (As, Cd, Cu, Cr,
633 Ni, Pb, and Zn) to a major European Estuary (Gironde Estuary, France) from urban wastewater. *Mar.*
634 *Chem.* 167, 123-134.

635 dos Santos, M. M., Hoppe-Jones, C., Snyder, S. A., 2019. DEET occurrence in wastewaters:
636 Seasonal, spatial and diurnal variability-mismatches between consumption data and environmental
637 detection. *Environ. Int.* 132, 105038.

638 Du, B., Lofton, J. M., Peter, K. T., Gipe, A. D., James, C. A., McIntyre, J. K., Scholz N.L., Baker,
639 J.E., Kolodziej, E. P., 2017. Development of suspect and non-target screening methods for detection
640 of organic contaminants in highway runoff and fish tissue with high-resolution time-of-flight mass
641 spectrometry. *Environ. Sci. Process. Impact* 19(9), 1185-1196.

642 Fulazzaky, M. A., Abdullah, N. H., Yusoff, A. R. M., Paul, E., 2015. Conditioning the alternating
643 aerobic–anoxic process to enhance the removal of inorganic nitrogen pollution from a municipal
644 wastewater in France. *J. Clean. Prod.* 100, 195-201.

645 Gasperi, J., Garnaud, S., Rocher, V., Moilleron, R., 2008. Priority pollutants in wastewater and
646 combined sewer overflow. *Sci. Total Environ.* 407(1), 263-272.

647 Gasperi, J., Zgheib, S., Cladière, M., Rocher, V., Moilleron, R., Chebbo, G., 2012. Priority pollutants
648 in urban stormwater: Part 2–Case of combined sewers. *Water Res.* 46(20), 6693-6703.

649 Gavrilescu, M., Demnerová, K., Aamand, J., Agathos, S., Fava, F., 2015. Emerging pollutants in the
650 environment: present and future challenges in biomonitoring, ecological risks and bioremediation.
651 *New Biotechnol.* 32(1), 147-156.

652 Göbel, A., McArdell, C. S., Joss, A., Siegrist, H., Giger, W., 2007. Fate of sulfonamides, macrolides,
653 and trimethoprim in different wastewater treatment technologies. *Sci. Total Environ.* 372(2-3), 361-
654 371.

655 Golovko, O., Kumar, V., Fedorova, G., Randak, T., Grabic, R., 2014. Seasonal changes in antibiotics,
656 antidepressants/psychiatric drugs, antihistamines and lipid regulators in a wastewater treatment plant.
657 *Chemosphere*, 111, 418-426.

658 Gosset, A., Durrieu, C., Orias, F., Bayard, R., Perrodin, Y., 2017. Identification and assessment of
659 ecotoxicological hazards attributable to pollutants in urban wet weather discharges. *Environ. Sci.*
660 *Process. Impact* 19(9), 1150-1168.

661 Gosset, A., Polomé, P., Perrodin, Y., 2020. Ecotoxicological risk assessment of micropollutants from
662 treated urban wastewater effluents for watercourses at a territorial scale: Application and comparison
663 of two approaches. *Int. J. Hyg. Environ. Health* 224, 113437.

664 Gros, M., Blum, K. M., Jernstedt, H., Renman, G., Rodríguez-Mozaz, S., Haglund, P., Andersson,
665 P.L., Wiberg, K., Ahrens, L., 2017. Screening and prioritization of micropollutants in wastewaters
666 from on-site sewage treatment facilities. *J. Hazard. Mater.* 328, 37-45.

667 Gros, M., Petrović, M., Ginebreda, A., Barceló, D., 2010. Removal of pharmaceuticals during
668 wastewater treatment and environmental risk assessment using hazard indexes. *Environ. Int.* 36(1),
669 15-26.

670 Guillosoy, R., Le Roux, J., Mailler, R., Vulliet, E., Morlay, C., Nauleau, F., Gasperi, J., Rocher, V.,
671 2019. Organic micropollutants in a large wastewater treatment plant: What are the benefits of an
672 advanced treatment by activated carbon adsorption in comparison to conventional treatment?.
673 *Chemosphere* 218, 1050-1060.

674 Gurke, R., Rößler, M., Marx, C., Diamond, S., Schubert, S., Oertel, R., Fauler, J., 2015. Occurrence
675 and removal of frequently prescribed pharmaceuticals and corresponding metabolites in wastewater
676 of a sewage treatment plant. *Sci. Total Environ.* 532, 762-770.

677 Hug, C., Ulrich, N., Schulze, T., Brack, W., Krauss, M., 2014. Identification of novel micropollutants
678 in wastewater by a combination of suspect and nontarget screening. *Environ. Pollut.* 184, 25-32.

679 INERIS,2020. Portail Substances Chimiques (French national database)
680 <https://substances.ineris.fr/fr/> (Last consultation : 11-03-2020)

681 Iranzo, M., Gamón, M., Boluda, R., Mormeneo, S., 2018. Analysis of pharmaceutical biodegradation
682 of WWTP sludge using composting and identification of certain microorganisms involved in the
683 process. *Sci. Total Environ.* 640, 840-848.

684 Jelic, A., Gros, M., Ginebreda, A., Cespedes-Sánchez, R., Ventura, F., Petrovic, M., Barcelo, D.,
685 2011. Occurrence, partition and removal of pharmaceuticals in sewage water and sludge during
686 wastewater treatment. *Water Res.* 45(3), 1165-1176.

687 Kimura, K., Hara, H., Watanabe, Y. (2005). Removal of pharmaceutical compounds by submerged
688 membrane bioreactors (MBRs). *Desalination*, 178(1-3), 135-140.

689 Köck-Schulmeyer, M., Villagrasa, M., de Alda, M. L., Céspedes-Sánchez, R., Ventura, F., Barceló,
690 D., 2013. Occurrence and behavior of pesticides in wastewater treatment plants and their
691 environmental impact. *Sci. Total Environ.* 458, 466-476.

692 Krauss, M., Hug, C., Bloch, R., Schulze, T., Brack, W., 2019. Prioritising site-specific
693 micropollutants in surface water from LC-HRMS non-target screening data using a rarity score. *Env.*
694 *Sci. Eur.* 31(1), 45.

695 Kümmerer, K., Dionysiou, D.D., Olsson, O., Fatta-Kassinos, D., 2019. Reducing aquatic
696 micropollutants - Increasing the focus on input prevention and integrated emission management. *Sci.*
697 *Total Environ.* 652, 836-850

698 Laquaz, M., Dagot, C., Wiest, L., Bazin, C., Gaschet, M., Perrodin, Y. 2020. Ecotoxicity and
699 antibiotic resistance of wastewater during transport in an urban sewage network. *Environ. Sci. Pollut.*
700 *Res.*

701 López-Pacheco, I., Silva-Núñez, A., Salinas-Salazar, C., Arévalo-Gallegos, A., Lizarazo-Holguin,
702 L. A., Barceló, D., Iqbal, H. M., Parra-Saldívar, R., 2019. Anthropogenic contaminants of high
703 concern: Existence in water resources and their adverse effects. *Sci. Total Environ.* 690, 1068-1088.

704 Luo, Y., Guo, W., Ngo, H. H., Nghiem, L. D., Hai, F. I., Zhang, J., Liang, S., Wang, X. C., 2014. A
705 review on the occurrence of micropollutants in the aquatic environment and their fate and removal
706 during wastewater treatment. *Sci. Total Environ.* 473, 619-641.

707 Martín, J., Camacho-Muñoz, D., Santos, J. L., Aparicio, I., Alonso, E., 2012. Occurrence of
708 pharmaceutical compounds in wastewater and sludge from wastewater treatment plants: removal and
709 ecotoxicological impact of wastewater discharges and sludge disposal. *J. Hazard. Mater.* 239, 40-47.

710 Merel S., Snyder S. A., 2016. Critical assessment of the ubiquitous occurrence and fate of the insect
711 repellent N,N-diethyl-m-toluamide in water. *Environ. Int.* 96, 98-117.

712 Miège, C., Favier, M., Brosse, C., Canler, J. P., Coquery, M., 2006. Occurrence of betablockers in
713 effluents of wastewater treatment plants from the Lyon area (France) and risk assessment for the
714 downstream rivers. *Talanta*, 70(4), 739-744.

715 Mohan, S., Balakrishnan, P., 2019. Triclosan in treated wastewater from a city wastewater treatment
716 plant and its environmental risk assessment. *Water Air Soil Pollut.* 230(3), 69.

717 Nannou, C., Ofrydopoulou, A., Evgenidou, E., Heath, D., Heath, E., Lambropoulou, D., 2020.
718 Antiviral drugs in aquatic environment and wastewater treatment plants: A review on occurrence,
719 fate, removal and ecotoxicity. *Sci. Total Environ.* 699, 134322.

720 Nefau, T., Karolak, S., Castillo, L., Boireau, V., Levi, Y., 2013. Presence of illicit drugs and
721 metabolites in influents and effluents of 25 sewage water treatment plants and map of drug
722 consumption in France. *Sci. Total Environ.* 461, 712-722.

723 Orias, F., Perrodin, Y., 2013. Characterisation of the ecotoxicity of hospital effluents: a review. *Sci.*
724 *Total Environ.* 454, 250-276.

725 Östman, M., Björleinius, B., Fick, J., Tysklind, M., 2019. Effect of full-scale ozonation and pilot-
726 scale granular activated carbon on the removal of biocides, antimycotics and antibiotics in a sewage
727 treatment plant. *Sci. Total Environ.* 649, 1117-1123.

728 Palli, L., Spina, F., Varese, G. C., Vincenzi, M., Aragno, M., Arcangeli, G., Mucci, N., Santianni,
729 D., Caffaz, S., Gori, R., 2019. Occurrence of selected pharmaceuticals in wastewater treatment plants
730 of Tuscany: An effect-based approach to evaluate the potential environmental impact. *Int. J. Hyg.*
731 *Environ. Health* 222(4), 717-725.

732 Pasquini, L., Munoz, J. F., Pons, M. N., Yvon, J., Dauchy, X., France, X., Le, N.D., France-Lanord,
733 C., Görner, T., 2014. Occurrence of eight household micropollutants in urban wastewater and their
734 fate in a wastewater treatment plant. Statistical evaluation. *Sci. Total Environ.* 481, 459-468.

735 Perrodin, Y., Bazin, C., Orias, F., Wigh, A., Bastide, T., Berlioz-Barbier, A., Vulliet, E., Wiest, L.,
736 2016. A posteriori assessment of ecotoxicological risks linked to building a hospital. *Chemosphere*
737 144, 440-445.

738 Petrie, B., Barden, R., Kasprzyk-Hordern, B., 2015. A review on emerging contaminants in
739 wastewaters and the environment: current knowledge, understudied areas and recommendations for
740 future monitoring. *Water Res.* 72, 3-27.

741 Pinasseau, L., Wiest, L., Fildier, A., Volatier, L., Fones, G. R., Mills, G. A., Mermillod-Blondin, F.,
742 Vulliet, E., 2019. Use of passive sampling and high resolution mass spectrometry using a suspect
743 screening approach to characterise emerging pollutants in contaminated groundwater and runoff. *Sci.*
744 *Total Environ.* 672, 253-263.

745 Ramírez-Morales, D., Masís-Mora, M., Montiel-Mora, J. R., Cambronero-Heinrichs, J. C., Briceño-
746 Guevara, S., Rojas-Sánchez, C. E., Rodríguez-Rodríguez, C. E., 2020. Occurrence of
747 pharmaceuticals, hazard assessment and ecotoxicological evaluation of wastewater treatment plants
748 in Costa Rica. *Sci. Total Environ.* 746, 141200.

749 Repice, C., Dal Grande, M., Maggi, R., Pedrazzani, R., 2013. Licit and illicit drugs in a wastewater
750 treatment plant in Verona, Italy. *Sci. Total Environ.* 463, 27-34.

751 Rogers, H. R., 1996. Sources, behaviour and fate of organic contaminants during sewage treatment
752 and in sewage sludges. *Sci. Total Environ.* 185(1-3), 3-26.

753 Santos, L. H., Gros, M., Rodriguez-Mozaz, S., Delerue-Matos, C., Pena, A., Barceló, D.,
754 Montenegro, M. C. B., 2013. Contribution of hospital effluents to the load of pharmaceuticals in
755 urban wastewaters: identification of ecologically relevant pharmaceuticals. *Sci. Total Environ.* 461,
756 302-316.

757 Sausseureau, E., Lacroix, C., Guerbet, M., Cellier, D., Spiroux, J., Goullé, J. P., 2013. Determination
758 of levels of current drugs in hospital and urban wastewater. *Bull. Environ. Contam. Toxicol.* 91(2),
759 171-176.

760 Schymanski, E.L., Jeon, J., Gulde R, Fenner, K., Ruff, M., Singer, H.P., Hollender, J. (2014).
761 Identifying Small Molecules via High Resolution Mass Spectrometry: Communicating Confidence.
762 *Environ. Sci. Technol.* 48, 2097-2098

763 Singer, H. P., Wössner, A. E., Mc Ardell, C. S., Fenner, K., 2016. Rapid screening for exposure to
764 “non-target” pharmaceuticals from wastewater effluents by combining HRMS-based suspect
765 screening and exposure modeling. *Environ. Sci. Technol.* 50(13), 6698-6707.

766 Sjerps, R. M., Vughs, D., van Leerdam, J. A., ter Laak, T. L., van Wezel, A. P., 2016. Data-driven
767 prioritization of chemicals for various water types using suspect screening LC-HRMS. *Water Res.*
768 93, 254-264.

769 Tlili, A., Hollender, J., Kienle, C., Behra, R., 2017. Micropollutant-induced tolerance of in situ
770 periphyton: establishing causality in wastewater-impacted streams. *Water Res.* 111, 185-194

771 Tran, N. H., Reinhard, M., Gin, K. Y. H., 2018. Occurrence and fate of emerging contaminants in
772 municipal wastewater treatment plants from different geographical regions—a review. *Water Res.* 133,
773 182-207.

774 Tsui, M. M., Leung, H. W., Lam, P. K., Murphy, M. B., 2014. Seasonal occurrence, removal
775 efficiencies and preliminary risk assessment of multiple classes of organic UV filters in wastewater
776 treatment plants. *Water Res.* 53, 58-67.

777 Verlicchi, P., Al Aukidy, M., Zambello, E., 2012. Occurrence of pharmaceutical compounds in urban
778 wastewater: removal, mass load and environmental risk after a secondary treatment—a review. *Sci.*
779 *Total Environ.* 429, 123-155.

780 Vidal, 2020. Le site de référence des professionnels de santé/The reference site for healthcare
781 professionals. (Last consultation: 11-03-2020). <https://www.vidal.fr/>

782 Vieno, N., Sillanpää, M., 2014. Fate of diclofenac in municipal wastewater treatment plant—a
783 review. *Environ. Int.* 69, 28-39.

784 Vulliet, E., Cren-Olivé, C., 2011. Screening of pharmaceuticals and hormones at the regional scale,
785 in surface and groundwaters intended to human consumption. *Environ. Pollut.* 159(10), 2929-2934.

786 Wang, Y., Gao, W., Wang, Y., Jiang, G., 2019. Suspect screening analysis of the occurrence and
787 removal of micropollutants by GC-QTOF MS during wastewater treatment processes. *J. Hazard.*
788 *Mater.* 376, 153-159.

789 Wiest, L., Chonova, T., Bergé, A., Baudot, R., Bessueille-Barbier, F., Ayouni-Derouiche, L., Vulliet,
790 E., 2018. Two-year survey of specific hospital wastewater treatment and its impact on
791 pharmaceutical discharges. *Environ. Sci. Pollut. Res.* 25(10), 9207-9218.

792 Wigh, A., Devaux, A., Brosselin, V., Gonzalez-Ospina, A., Domenjoud, B., Aït-Aïssa, S., Creusot,
793 N., Gosset, A., Bazin, C., Bony, S., 2016. Proposal to optimize ecotoxicological evaluation of
794 wastewater treated by conventional biological and ozonation processes. *Environ. Sci. Pollut. Res.*
795 23(4), 3008-3017.

796 Yadav, M. K., Short, M. D., Gerber, C., van den Akker, B., Aryal, R., Saint, C. P., 2019. Occurrence,
797 removal and environmental risk of markers of five drugs of abuse in urban wastewater systems in
798 South Australia. *Environ. Sci. Pollut. Res.* 26(33), 33816-33826.

799 Yan, Q., Gao, X., Chen, Y. P., Peng, X. Y., Zhang, Y. X., Gan, X. M., Zi, C.-F., Guo, J. S., 2014.
800 Occurrence, fate and ecotoxicological assessment of pharmaceutically active compounds in
801 wastewater and sludge from wastewater treatment plants in Chongqing, the Three Gorges Reservoir
802 Area. *Sci. Total Environ.* 470, 618-630.

803 Zhou, S., Di Paolo, C., Wu, X., Shao, Y., Seiler, T. B., Hollert, H. (2019). Optimization of screening-
804 level risk assessment and priority selection of emerging pollutants–The case of pharmaceuticals in
805 European surface waters. *Environ. Int.* 128, 1-10.

806 Zorita, S., Mårtensson, L., Mathiasson, L., 2009. Occurrence and removal of pharmaceuticals in a
807 municipal sewage treatment system in the south of Sweden. *Sci. Total Environ.* 407(8), 2760-2770.

808

809

810

811

812

813

814

815

816

817 List of the figures

818 Figure 1: Location of the 10 studied WWTPs on the Lyon (France) urbanized area.

819 Figure 2: Schematic of performed LC-QToF-MS analyses

820 Figure 3: Number of scientific studies devoted to each detected compound and wastewaters or
821 urban/municipal wastewaters (Web of Knowledge search, last consultation: 04-01-2020).

822 Figure 4: Box plot (min., quartiles, median, max.) of the concentrations of each identified EP in
823 influent for all WWTPs and sampling campaigns (n=30). Only concentrations above the limit of
824 quantification (LOQ) are considered. The specific number of values for each EP is specified in the
825 brackets. The dot corresponds to the mean.

826 Figure 5: Box plot (min., quartiles, median, max.) of the overall removal rates (%) of each EP
827 identified in this study for all WWTPs and sampling campaigns (n=30). The specific number of
828 calculated values for each EP is specified in the brackets. The dot corresponds to the mean.

829 Figure 6: Box plot (min., quartiles, median, max.) of the concentrations of each identified EP in
830 effluent for all WWTPs and sampling campaigns (n=30). Only concentrations above the limit of
831 quantification (LOQ) are considered. The specific number of values for each EP is specified in the
832 brackets. The dot corresponds to the mean

833





Figure 1: Location of the 10 studied WWTPs on the Lyon (France) urbanized area.



843

844 Figure 2: Schematic of performed LC-QToF-MS analyses.

845

846

847

848

849

850

851

852

853

854


855

856

857

858

859



860 Figure 3: Number of scientific studies devoted to each detected compound and wastewaters or
 861 urban/municipal wastewaters (Web of Knowledge search, last consultation: 04-01-2020).

862

863

864

865

866

867

868


869

870

871

872


873



874

875 Figure 4: Box plot (min., quartiles, median, max.) of the concentrations of each identified EP in
 876 influent for all WWTPs and sampling campaigns (n=30). Only concentrations above the limit of
 877 quantification (LOQ) are considered. The specific number of values for each EP is specified in the
 878 brackets. The dot corresponds to the mean.


879
880
881



882

883 Figure 5: Box plot (min., quartiles, median, max.) of the overall removal rates (%) of each EP
884 identified in this study for all WWTPs and sampling campaigns (n=30). The specific number of
885 calculated values for each EP is specified in the brackets. The dot corresponds to the mean.

886



887 Figure 6: Box plot (min., quartiles, median, max.) of the concentrations of each identified EP in
 888 effluent for all WWTPs and sampling campaigns (n=30). Only concentrations above the limit of
 889 quantification (LOQ) are considered. The specific number of values for each EP is specified in the
 890 brackets. The dot corresponds to the mean.

Table 1: Characteristics of the 10 studied WWTPs

| N° | Incoming load in Population Equivalent (PE) | Incoming annual flow rate of the WWTP (m ³ /day) | Design capacity (PE) | Design flow rate (m ³ /day) | Pretreatment | Primary treatment | Secondary treatment | Tertiary treatment | Influent - Sampling location | Effluent - Sampling location |
|----|---|---|----------------------|--|--|---|---|---|------------------------------|------------------------------|
| 1 | 772 | 235 | 1433 | 320 | Screening, grit chamber and grease remover | None | Activated sludges | None | Pretreatment outlet | Secondary treatment outlet |
| 2 | 2843 | 679 | 3830 | 900 | Screening, grit chamber and grease remover | Sedimentation tank | Activated sludges | None | Pretreatment inlet | Secondary treatment outlet |
| 3 | 9150 | 1300 | 10000 | 1300 | Screening, grit chamber and grease remover | Buffer tank | Radial flow fluidized filter/ Syncopated aeration | None | WWTP inlet | Secondary treatment outlet |
| 4 | 25732 | 4016 | 33300 | 8730 | Screening, grit chamber and grease remover | Sedimentation tank | Biofilter | None | Pretreatment inlet | Secondary treatment outlet |
| 5 | 21800 | 5544 | 42000 | 9900 | Screening, grit chamber and grease remover | Sedimentation tank | Activated sludges | None | Pretreatment inlet | Secondary treatment outlet |
| 6 | 16165 | 6745 | 34100 | 18000 | Screening, grit chamber and grease remover | Coagulation-flocculation and sedimentation tank | Activated sludges | None | Pretreatment inlet | Secondary treatment outlet |
| 7 | 44087 | 8980 | 30000 | 9670 | Screening, grit chamber and grease remover | Sedimentation tank | Biofilter | None | Pretreatment inlet | Secondary treatment outlet |
| 8 | 179772 | 38188 | 300000 | 91000 | Screening, grit chamber and grease remover | Sedimentation tank | Activated sludges | None | WWTP inlet | Secondary treatment outlet |
| 9 | 524325 | 156962 | 950000 | 300000 | Screening, grit chamber and grease remover | Sedimentation tank | Activated sludges | None | Pretreatment inlet | Secondary treatment outlet |
| 10 | 622800 | 215092 | 983000 | 554000 | Screening, grit chamber and grease remover | Sedimentation tank | Activated sludges | Biofiltration (Suspended solids, carbon and nitrogen pollution removal) | WWTP inlet | Tertiary treatment outlet |

892

893 Table 2: Classical physico-chemical parameters measured on influent and effluent samples.

| Parameter | Unit | Influents | | | | | Effluents | | | | |
|-------------------------------|--------------------------|-----------|---------|---------|---------|-------|-----------|--------|--------|---------|-------|
| | | Min | Median | Mean | Max | Freq. | Min | Median | Mean | Max | Freq. |
| pH | pH unit | 7.40 | 7.80 | 7.81 | 8.00 | X | 7.50 | 7.90 | 7.88 | 8.10 | X |
| Conductivity | $\mu\text{S/cm}$ at 25°C | 989.00 | 1160.00 | 1243.40 | 1793.00 | X | 617.00 | 953.5 | 994.9 | 1258.00 | X |
| TSS | mg/L | 81.00 | 279.00 | 270.80 | 450.00 | 30/30 | 3.00 | 8 | 12.9 | 36 | 30/30 |
| COD | mg O ₂ /L | 105.00 | 616.00 | 588.37 | 982.00 | 30/30 | 13.00 | 32.85 | 41.313 | 109 | 30/30 |
| Cl ⁻ | mg/L | 57.75 | 114.45 | 135.45 | 361.68 | 30/30 | 57.38 | 121.97 | 126.82 | 222.97 | 30/30 |
| NO ₂ ⁻ | mg/L | n.d. | 0.62 | 0.75 | 1.83 | 6/30 | n.d. | 1.50 | 1.61 | 3.78 | 9/30 |
| NO ₃ ⁻ | mg/L | n.d. | 6.39 | 8.64 | 40.40 | 25/30 | 1.87 | 18.07 | 32.53 | 139.38 | 30/30 |
| PO ₄ ³⁻ | mg/L | n.d. | 9.37 | 9.71 | 18.62 | 28/30 | n.d. | 5.96 | 6.59 | 14.90 | 21/30 |
| SO ₄ ²⁻ | mg/L | 39.81 | 53.99 | 55.44 | 110.08 | 30/30 | 35.41 | 51.21 | 53.53 | 92.01 | 30/30 |
| NH ₄ ⁺ | mg/L | 6.68 | 48.84 | 47.38 | 81.66 | 30/30 | 0.34 | 4.67 | 15.62 | 63.58 | 30/30 |
| K ⁺ | mg/L | 5.85 | 17.57 | 18.02 | 27.34 | 30/30 | 4.83 | 15.68 | 16.31 | 32.73 | 30/30 |

894 n.d.: Not detected.; Freq.: Number of values different from "n.d."; COD: Chemical Oxygen Demand; TSS; Total Suspended Solids

895

896

897

898

899 Table 3: Overall removal (%) of identified emerging pollutants in this study compared to urban and conventional WWTPs worldwide. ND: No data in literature.

900 MRR: Median removal rate.

| | This study | | | Archer et al., 2017 | Burns et al., 2018 | Campo et al., 2013 | Couto et al., 2019 | Deblonde et al., 2011 | Golovko et al., 2014 | Gurke et al., 2015 | Luo et al., 2014 | Nannou et al., 2020 | Repice et al., 2013 | Santos et al., 2013 | Saussereau et al., 2013 | Tran et al., 2018 | Yadav et al., 2019 | | |
|------------------|---|----------------|--------------|---------------------------|------------------------------|---------------------|------------------------------------|---------------------------------------|-----------------------------|----------------------|---------------------------------------|---------------------------------------|---------------------|-----------------------|-------------------------|-------------------------------------|-------------------------|--------|-----------|
| | Urban WWTPs | | | Urban WWTP - South Africa | Urban WWTPs - United Kingdom | Urban WWTPs - Spain | Review - Municipal WWTPs worldwide | Review - All types of WWTPs worldwide | Urban WWTP - Czech Republic | Urban WWTP - Germany | Review - Conventional WWTPs worldwide | Review - All types of WWTPs worldwide | Urban WWTP - Italie | Urban WWTP - Portugal | Urban WWTP - France | Review - Full-scale WWTPs worldwide | Urban WWTPs - Australia | | |
| Removal (%) | Removal category | Median removal | Mean removal | Mean | Range | Mean | Range | Mean | Mean | Mean | Range | Range | Mean | Range | Mean | Annual removal | Range | Mean | |
| Benzoylecgonine | High removal efficiency (MRR >70 %) | 92.94 | 72.18 | 98 | | | | | | | | | 90 | | | | | 75 | |
| Telmisartan | | 90.74 | 88.53 | | | | | | | 45.5 | | | | | | | | | |
| Naproxen | | 89.71 | 76.21 | 47 | | | | 0-90 | 81.6 | | | 43.3-98.6 | | | <0-90 | 53 | | | <0-99.3 |
| Gabapentin | | 86.33 | 62.50 | | | 87.4-97.9 | | | | | 6.4 | | | | | | | | <0-95.6 |
| Acebutolol | | 80.35 | 71.91 | | | | | | 58.2 | | | | | | | | 52 | | |
| Ketoprofen | | 79.17 | 72.40 | 77 | | | | 98.7 | 31.1 | | | 10.8-100 | | | 35-68 | 53 | | | 51.5-91.9 |
| Fexofenadine | | 73.07 | 73.80 | 49 | | 0.47-22.9 | | | | 11 | | | | | | | | | |
| Rosuvastatin | Moderate removal efficiency (30 % < MRR < 70 %) | 67.31 | 64.53 | | | | | | 68 | | | | | | | | | | |
| Atenolol | | 66.80 | 62.75 | 75 | | 90.7-94.8 | | 48-100 | 56.7 | | 22.6 | | | <0-21 | <0 | | | <0-96 | |
| DEET | | 62.82 | 40.17 | | | | | | | | | 65.6-79.5 | | | | | | 27-100 | |
| Valsartan | | 59.21 | 42.82 | 90 | | | | | | | 24.4 | | | <0-100 | 52 | | | | |
| Atorvastatin | | 56.48 | 55.64 | 67 | | | | 66.7 | | 93 | | | | | | | | | |
| Sulfamethoxazole | | 53.76 | 46.15 | 18 | | 37.2-92.8 | | 36-68 | 17.5 | 58 | 42.4 | 4-88.9 | | | <0-41 | 12 | | | <0-99 |
| Verapamil | | 45.89 | 42.74 | | | 20-20 | | | | | | | | | 18-75 | 45 | 57 | | |
| Citalopram | | 39.57 | 42.64 | | | (-7.2)-30.3 | | | | 18 | 6.3 | | | | <0-28 | <0 | | | |
| Trospium | | 39.06 | 33.21 | ND | | | | | | | | | | | | | | | |
| Trimethoprim | | 34.86 | 34.49 | 80 | | 56.7-74.7 | | 1-99 | 1.4 | | -10.6 | <0-81.6 | | | <0-20 | <0 | | | |
| Sitagliptin | | 31.42 | 32.76 | | | 24.4-44.1 | | | | | | | | | | | | | |
| Codeine | | 30.76 | 25.93 | 74 | | 93.5-95.5 | | | | | | | | | 1-93 | 38 | 4.8 | | <0-98 |
| Celiprolol | 30.69 | 21.90 | | | | | | 36.4 | | -1.1 | | | | | | 7.8 | | | |

| | | | | | | | | | | | | | | | | | | | |
|---------------|--|--------|---------|----|----------------|-------|---------|------|-----|------|--|--|--|--|-------|----|-----|-------|-------|
| Bisoprolol | | 29.08 | 23.34 | | | | | | | 20.3 | | | | | | 36 | | | |
| Methocarbamol | | 28.92 | 21.86 | ND | | | | | | | | | | | | | | | |
| Amantadine | | 28.59 | 23.72 | | | | | | | | | | | | | | | | |
| Fluopyram | | 26.74 | 26.74 | ND | | | | | | | | | | | | | | | |
| Cetirizine | | 24.71 | 25.34 | | | | | | | | | | | | | | 8.1 | | |
| Amisulpride | | 22.76 | 24.93 | ND | | | | | | | | | | | | | | | |
| Oxazepam | | 21.97 | 24.41 | | (-26)- 38.7 | | 39.8 | | -17 | | | | | | | | 7.5 | | |
| Milnacipran | | 21.38 | 14.34 | ND | | | | | | | | | | | | | | | |
| Flecainide | | 18.47 | 13.65 | | | | | | | | | | | | | | 2.8 | | |
| Diclofenac | | 18.36 | 16.39 | 47 | | | 46.8-94 | 34.6 | | | | | | | | | | | <0-98 |
| EDDP | | 17.86 | 15.50 | 5 | | | | | | | | | | | | | | | |
| Carbamazepine | | 15.75 | 11.80 | 13 | 0.36- 25.1 | | 0-94.9 | -5.7 | -12 | -6.6 | | | | | 6-31 | 19 | <0 | <0-83 | |
| Venlafaxine | | 14.55 | 17.80 | 60 | 16.8- 66.3 | | | | 1 | 7.7 | | | | | <0-11 | <0 | | | |
| Terbutryn | | 12.34 | -6.07 | | | 24,19 | | | | | | | | | | | | | |
| Disopyramide | | 10.59 | 6.25 | | | | | | | | | | | | | | | 0 | |
| Lidocaine | | 6.49 | 27.10 | | 11.7- 27.4 | | | | | | | | | | | | | <0 | |
| Fluconazole | | 2.49 | 3.50 | | | | | | | 15.4 | | | | | | | | | |
| Diuron | | -7.55 | -113.45 | | | | | | | | | | | | | | | | |
| Irbesartan | | -9.49 | -12.99 | 28 | | | | | | 8.1 | | | | | <0-88 | <0 | | | |
| Tiapride | | -49.80 | -41.54 | ND | | | | | | | | | | | | | | | |
| Clopidogrel | | -96.73 | -110.46 | | | | | | | | | | | | <0-69 | 21 | | | |

901

902

903